Baseline clinical characteristics
| . | Rituximab-treated subjects (n = 65) . | Controls (n = 68) . | . | ||
|---|---|---|---|---|---|
| . | N . | % . | N . | % . | P value . |
| Age, median (range) | 54 (19-74) | 54 (26-70) | .81 | ||
| Gender | 1.00 | ||||
| M | 39 | 60 | 41 | 60.3 | |
| F | 26 | 40 | 27 | 39.7 | |
| Donor gender | 1.00 | ||||
| M | 38 | 58.5 | 39 | 57.4 | |
| F | 27 | 41.5 | 29 | 42.6 | |
| Subject–donor gender | .87 | ||||
| FF | 9 | 13.8 | 12 | 17.6 | |
| FM | 17 | 26.2 | 15 | 22.1 | |
| MF | 18 | 27.7 | 17 | 25 | |
| MM | 21 | 32.3 | 24 | 35.3 | |
| Diagnosis | .57 | ||||
| AML | 30 | 46.2 | 31 | 45.6 | |
| CLL/SLL/PLL | 2 | 3.1 | 3 | 4.4 | |
| HD | 1 | 1.5 | 1 | 1.5 | |
| ALL | 4 | 6.2 | 5 | 7.4 | |
| MDS | 6 | 11.1 | 7 | 10.3 | |
| MPD | 4 | 6.2 | |||
| Mixed MDS/MPD | 1 | 1.5 | |||
| NHL | 18 | 27.7 | 20 | 29.4 | |
| Disease relapse index | .49 | ||||
| Low | 10 | 15.4 | 10 | 14.7 | |
| Intermediate | 38 | 58.5 | 32 | 47.1 | |
| High | 15 | 23.1 | 22 | 32.4 | |
| Very high | 2 | 3.1 | 4 | 5.9 | |
| Disease status at transplantation | |||||
| Active | 30 | 46.1 | 28 | 41.2 | .60 |
| Remission | 35 | 53.8 | 40 | 58.8 | |
| Donor type | |||||
| 8/8 MRD | 31 | 47.7 | 30 | 44.1 | .52 |
| 8/8 MUD | 33 | 50.8 | 38 | 55.9 | |
| 7/8 mismatched unrelated | 1 | 1.5 | |||
| Conditioning intensity | |||||
| MAC | 25 | 38.5 | 28 | 41.2 | .86 |
| RIC | 40 | 61.5 | 40 | 58.8 | |
| Stem cell source | |||||
| PBSC | 65 | 100 | 68 | 100 | 1.00 |
| GVHD prophylaxis regimen | |||||
| CI+/− Mtx+/− other | 22 | 33.8 | 26 | 38.2 | .72 |
| CI+/− Siro+/− other | 43 | 66.2 | 42 | 61.8 | |
| Grade II-IV acute GVHD | 9 | 13.8 | 12 | 17.6 | .64 |
| Grade III-IV acute GVHD | 2 | 3.1 | 5 | 7.4 | .44 |
| Corticosteroid use at rituximab initiation/day 100 | 5 | 7.7 | 9 | 13.2 | .57 |
| Corticosteroid dose (mg/kg) at rituximab initiation/day 100 (median, range) | 0.13 | (0.06-0.38) | 0.34 | (0.11-0.93) | .09 |
| . | Rituximab-treated subjects (n = 65) . | Controls (n = 68) . | . | ||
|---|---|---|---|---|---|
| . | N . | % . | N . | % . | P value . |
| Age, median (range) | 54 (19-74) | 54 (26-70) | .81 | ||
| Gender | 1.00 | ||||
| M | 39 | 60 | 41 | 60.3 | |
| F | 26 | 40 | 27 | 39.7 | |
| Donor gender | 1.00 | ||||
| M | 38 | 58.5 | 39 | 57.4 | |
| F | 27 | 41.5 | 29 | 42.6 | |
| Subject–donor gender | .87 | ||||
| FF | 9 | 13.8 | 12 | 17.6 | |
| FM | 17 | 26.2 | 15 | 22.1 | |
| MF | 18 | 27.7 | 17 | 25 | |
| MM | 21 | 32.3 | 24 | 35.3 | |
| Diagnosis | .57 | ||||
| AML | 30 | 46.2 | 31 | 45.6 | |
| CLL/SLL/PLL | 2 | 3.1 | 3 | 4.4 | |
| HD | 1 | 1.5 | 1 | 1.5 | |
| ALL | 4 | 6.2 | 5 | 7.4 | |
| MDS | 6 | 11.1 | 7 | 10.3 | |
| MPD | 4 | 6.2 | |||
| Mixed MDS/MPD | 1 | 1.5 | |||
| NHL | 18 | 27.7 | 20 | 29.4 | |
| Disease relapse index | .49 | ||||
| Low | 10 | 15.4 | 10 | 14.7 | |
| Intermediate | 38 | 58.5 | 32 | 47.1 | |
| High | 15 | 23.1 | 22 | 32.4 | |
| Very high | 2 | 3.1 | 4 | 5.9 | |
| Disease status at transplantation | |||||
| Active | 30 | 46.1 | 28 | 41.2 | .60 |
| Remission | 35 | 53.8 | 40 | 58.8 | |
| Donor type | |||||
| 8/8 MRD | 31 | 47.7 | 30 | 44.1 | .52 |
| 8/8 MUD | 33 | 50.8 | 38 | 55.9 | |
| 7/8 mismatched unrelated | 1 | 1.5 | |||
| Conditioning intensity | |||||
| MAC | 25 | 38.5 | 28 | 41.2 | .86 |
| RIC | 40 | 61.5 | 40 | 58.8 | |
| Stem cell source | |||||
| PBSC | 65 | 100 | 68 | 100 | 1.00 |
| GVHD prophylaxis regimen | |||||
| CI+/− Mtx+/− other | 22 | 33.8 | 26 | 38.2 | .72 |
| CI+/− Siro+/− other | 43 | 66.2 | 42 | 61.8 | |
| Grade II-IV acute GVHD | 9 | 13.8 | 12 | 17.6 | .64 |
| Grade III-IV acute GVHD | 2 | 3.1 | 5 | 7.4 | .44 |
| Corticosteroid use at rituximab initiation/day 100 | 5 | 7.7 | 9 | 13.2 | .57 |
| Corticosteroid dose (mg/kg) at rituximab initiation/day 100 (median, range) | 0.13 | (0.06-0.38) | 0.34 | (0.11-0.93) | .09 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, calcineurin inhibitor; CLL/SLL/PLL, chronic lymphocytic leukemia/small lymphocytic lymphoma/prolymphocytic Leukemia; F, Female; HD, Hodgkin Disease; M, Male; MAC, myeloablative conditioning; MDS, myelodysplastic disorder; MPD, myeloproliferative disease; MRD, matched, related donor; Mtx, methotrexate; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cells; RIC, reduced intensity conditioning.